Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide add-on for Parkinson's disease-related chronic pain
2017-002426-20Phase 4Completed
- Sponsor
- Zambon
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing Safinamide add-on with Placebo add-on (2 arms). Primary endpoint: Change in pain severity at week 16. Started Aug 2018; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-002426-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002426-20.